Since a correlation between ANRIL levels and IL6 and IL8 levels was found in CAD patients and elevated IL8 levels are associated with CAD risk [104], ANRIL may be a potential therapeutic target for CAD. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.